Expression and clinical significance of Bmi-1 protein in bladder cancer

vs. 81.5%, p 0.05). The patients were followed up for 44–86 months, with a median of 66 months. The 5-year survival rate was significantly higher in superficial bladder cancer patients than in invasive bladder cancer patients (89.6% vs. 39.2%, p < 0.05), and higher in Bmi-1-negative patients than in Bmi-1-positive patients (78.5% vs. 50.8%, p < 0.05). Conclusions: Bmi-1 protein is highly expressed in bladder cancer. Detecting Bmi-1 protein is helpful for the diagnosis and prognostic evaluation of bladder cancer. The incidence and progression of bladder carcinoma are the result of synergic actions of intrinsic and extrinsic factors on a body. Bladder carcinoma is a complicated, multi-factorial, and multi-step pathophysiological process, involving the activation of oncogenes and the deactivation of tumor suppressor genes. Although the grading and staging of tumors play an important role in determining the therapeutic outcomes and prognoses for bladder carcinoma, these indices still cannot fully reflect its biological characteristics. This research measures the expression of Bmi-1 protein in tumorous tissues of the bladder to investigate its relationship to the clinical manifestations, pathology, and prognosis of bladder carcinoma.